Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: Possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients?

Journal of Clinical Psychopharmacology

Volumn 27, Issue 2, 2007, Pages 188-192

  Reed, Laurence J ^a,b   Glasper, Anthony ^a,c,e   De Wet, Cornelis J ^a,d   Bearn, Jennifer ^a,b   Gossop, Michael ^a,b  

^a BETHLEM ROYAL HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c East Sussex Healthcare NHS Trust   (United Kingdom)

^d St Ann s Hospital   (United Kingdom)

^e Hastings and Rother Substance Misuse Service   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; METHADONE; OPIATE;

ADULT; ARTICLE; DISEASE SEVERITY; DRUG DETOXIFICATION; DRUG EFFICACY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; WITHDRAWAL SYNDROME;

ADULT; ANTI-ANXIETY AGENTS; BENZODIAZEPINES; BUPRENORPHINE; DIAZEPAM; FEMALE; HUMANS; MALE; METHADONE; NARCOTIC ANTAGONISTS; OPIOID PEPTIDES; OPIOID-RELATED DISORDERS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 34247105435     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e318032ec2a     Document Type: Article

References (35)

1. Mattick RP, Hall W. Are detoxification programmes effective? Lancet. 1996;347:97-100.
2. Milby JB. Methadone maintenance to abstinence. How many make it? J Nerv Ment Dis. 1988;176(7):409-422.
3. Amato L, Davoli M, Ferri M, et al. Effectiveness of interventions on opiate withdrawal treatment: an overview of systematic reviews. Drug Alcohol Depend. 2004;73(3):219-226.
4. Kleber HD, Riordan CE. The treatment of narcotic withdrawal: a historical review. J Clin Psychiatry. 1982;43(6):30-34.
5. Kreek MJ. Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci. 2000;909:186-216.
6. Gossop M, Griffiths P, Bradley B, et al. Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. Br J Psychiatry. 1989;154:360-363.
7. White R, Alcorn R, Feinmann C. Two methods of community detoxification from opiates: an open-label comparison of lofexidine and buprenorphine. Drug Alcohol Depend. 2001;65:77-83.
8. Gowing L, Ali R, White J. Buprenorphine for the management of opioid withdrawal (Cochrane Review) The Cochrane Library, Issue 3. Chichester, UK: John Wiley & Sons, Ltd.; 2004.
9. Ling W, Wesson D. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend. 2003;70:S49-S57.
10. Bickel WK, Stitzer ML, Bigelow GE, et al. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther. 1988;43:72-78.
11. Johnson R, Jaffe J, Fudala P. A controlled trial of buprenorphine treatment for opioid dependence. JAMA. 1992;267:2750-2755.
12. De Wet C, Reed L, Glasper A, et al. Benzodiazepine co-dependence exacerbates the opiate withdrawal syndrome. Drug Alcohol Depend. 2004;76(1):31-35.
13. Marsden J, Gossop M, Stewart D. The Maudsley Addiction Profile (MAP): a brief instrument for assessing treatment outcome. Addiction. 1998;93:1857-1868.
14. Gossop M. The development of a Short Opiate Withdrawal Scale (SOWS). Addict Behav. 1990;15(5):487-490.
15. Glasper A, Reed LJ, De Wet CJ, et al. Induction of patients with moderately severe methadone dependence onto buprenorphine. Addict Biol. 2005;10:149-155.
16. Strain EC. Methadone dose during maintenance treatment. In: Strain E, Stitzer M, eds. Methadone Treatment for Opioid Dependence. Baltimore, MD: Johns Hopkins University Press; 1999.
17. Gossop M, Marsden J, Stewart D, et al. Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Depend. 2001;62:255-264.
18. Seifert J, Metzner C, Paetzold W, et al. Detoxification of opiate addicts with multiple drug abuse: a comparison of buprenorphine vs methadone. Pharmacopsychiatry. 2002;35:159-164.
19. Umbricht A, Hoover D, Tucker M, et al. Opioid detoxification with buprenorphine, clonidine, or methadone in hospitalised heroin-dependent patients with HIV infection. Drug Alcohol Depend. 2003;69:263-272.
20. Smolka M, Schmidt LG. The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome. Addiction. 1999;94(8):1191-1198.
21. O'Connor PG, Carroll KM, Shi JM, et al. Three methods of opioid detoxification in a primary care setting. A randomized trial. Ann Intern Med. 1997;127:526-530.
22. Janini L, Mannelli P, Persico A, et al. Opiate detoxification of methadone maintenance patients using lefetamine, clonidine and buprenorphine. Drug Alcohol Depend. 1994;36:139-145.
23. Bullingham RES, McQuay HJ, Moore A, et al. Buprenorphine kinetics. Clin Pharmacol Ther. 1980;244:126-132.
24. Hambrook JM, Rance MJ. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. In: Kosterlitz HW, ed. Opiates and Endogenous Opioid Peptides. Amsterdam: Elsevier/North Holland Biomedical Press; 1976: 295-301.
25. Lewis JW. Buprenorphine. Drug Alcohol Depend. 1985;14:363-372.
26. Gossop M. A web of dependence. Addiction. 2001;96:677-678.
27. Gossop M, Marsden J, Stewart D. Dual dependence: assessment of dependence upon alcohol and illicit drugs, and the relationship of alcohol dependence among drug misusers to patterns of drinking, illicit drug use, and health problems. Addiction. 2002;97:169-178.
28. Chatham LR, Rowan-Szal GA, Joe GW, et al. Heavy drinking, alcohol dependent vs. nondependent methadone maintenance clients: A follow-up study. Addict Behav. 1997;22:69-80.
29. McKay JR, Alterman AI, Rutherford MJ, et al. The relationship of alcohol use to cocaine relapse in cocaine dependent patients in an aftercare study. J Stud Alcohol. 1999;60:176-180.
30. Stitzer M, Bigelow G, Liebson I, et al. Contingent reinforcement of benzodiazepine-free urines. J Appl Behav Anal. 1982;15:493-503.
31. Strang J, Griffiths P, Abbey J, et al. Survey of use of injected benzodiazepines among drug users in Britain. Br Med J. 1994;308:1082.
32. Kalyuzhny AE, Dooyema J, Wessendorf MW. Opioid- and GABA(A)-receptors are coexpressed by neurons in rat brain. Neuroreport. 2000;21:2625-2628.
33. Sasaki K, Fan LW, Tien LT, et al. The interaction of morphine and gamma-aminobutyric acid (GABA) ergic systems in anxiolytic behaviour using mu-opioid receptor knockout mice. Brain Res Bull. 2002;57:689-694.
34. Debruyne D, Quentin T, Poisnel G, et al. Acute and chronic administration of clorazepate modifies the cell surface regulation of mu opioid receptors induced by buprenorphine in specific regions of the rat brain. Brain Res. 2005;1052:222-231.
35. Phillips GT, Gossop M, Bradley B. The influence of psychological factors on the opiate withdrawal syndrome. Br J Psychiatry. 1986;149:235-238.